# A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Source: https://onco.cc/trials/nct07491497/  
OnCo record `nct07491497` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TRI-611 in non-small-cell lung cancer and small-cell lung cancer, run by TRIANA Biomedicines, Inc., now recruiting.

## Summary

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC is a phase 1/2 interventional study registered as NCT07491497 by TRIANA Biomedicines, Inc., with 160 participants planned, started 2026-03-11 and due to reach its primary completion in 2029-05-31. Interventions recorded: TRI-611. Conditions listed: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07491497
- Phase: 1/2
- Setting: A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC
- Sponsor: TRIANA Biomedicines, Inc.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07491497: https://clinicaltrials.gov/study/NCT07491497

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [TRI-611](https://onco.cc/drugs/tri-611/)
- companies: [Triana Biomedicines](https://onco.cc/companies/triana-biomedicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07491497.json